Oppenheimer initiated coverage of Wave Life Sciences (WVE) with an Outperform rating and $24 price target The firm views Wave as a leading innovator in advancing RNA medicine with four clinical-stage programs. The analyst is optimistic about WVE-006 and WVE-007, saying they represent first-in-class programs. Opco sees catalysts from both programs in the second half of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences initiated with a Buy at Citi
- Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating
- Wave Life Sciences: Promising RNA Editing Developments and Positive Stock Outlook
- Wave Life Sciences’ WVE-007: Undervalued Potential in Obesity Treatment with Promising Preclinical Results
- Wave Life Sciences assumed with an Outperform at Raymond James